Sevelamer Carbonate Drug Asset Due Diligence Report 2026

This Sevelamer Carbonate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Sevelamer Carbonate can convert its Polymer profile and Phosphates biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Sevelamer Carbonate (query alias: sevelamer)
Modality / target	Polymer; Phosphates; Phosphates modulators
Highest global status	Approved
Originator	Genzyme Corp.
Active developers	Sanofi Winthrop Industrie SA, Shandong Xinhua Pharmaceutical Co., Ltd., Kexing Biopharm Co., Ltd.

The MCP disease footprint includes Chronic Kidney Disease-Mineral and Bone Disorder, Hyperphosphatemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
TCTR20241128003	Phase 3	Completed	140	Not disclosed
PACTR202408492665945	Phase 3	Pending	135	Not disclosed
IRCT20210720051946N7	Phase 2/3	Recruiting	60	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects

Phase 4; n=44; evaluation: not stated. Reported fields: AUC(Geometric Mean) = 16300 ng*h/mL (Geometric Coefficient of Variation, 39.6); -; -

Efficacy, tolerability, and safety of the oral phosphate binder VS-505 (AP301).

Phase 2; n=130; evaluation: Positive. Reported fields: Serum phosphate = -1.6 mg/dL (95%CI, -2.2 to -1.0); -; Serum phosphate = -1.8 mg/dL (95%CI, -2.4 to 1.2)

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with hyperphosphataemia: A randomised, open-label, multicentre, 12-week phase III study.

Phase 3; n=286; evaluation: Positive. Reported fields: sP = -0.63 mmol/L ; sP = -0.71 mmol/L

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Sevelamer Carbonate addresses Chronic Kidney Disease-Mineral and Bone Disorder, Hyperphosphatemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Polymer—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-02-11	Handok to co-promote Sanofi Aventis’ hyperphosphatemia treatment	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Preparation method of sevelamer carbonate”. The milestone feed surfaced a patent-application signal described as “Preparation method of sevelamer carbonate”. The milestone feed surfaced a patent-application signal described as “Post-treatment method and preparation method of sevelamer carbonate”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO